Amyotrophic Lateral Sclerosis market size was USD 490 million in 2021

The Amyotrophic Lateral Sclerosis Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development.

The Amyotrophic Lateral Sclerosis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current Amyotrophic Lateral Sclerosis treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Amyotrophic Lateral Sclerosis Market Research Report
• The Amyotrophic Lateral Sclerosis market size in 7MM and China is expected to rise from USD 490 million in 2021 during the study period (2019-2032)..
• The total diagnosed cases of Amyotrophic Lateral Sclerosis was 59,130 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
• Amyotrophic Lateral Sclerosis Companies are working such as Helixmith, Sanofi, Denali Therapeutics, Alector,GSK, NeuroSense Therapeutics, Biogen, Ionis,Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others
• Amyotrophic Lateral Sclerosis Pipeline Therapies such as RILUTEK, TIGLUTIK, EXSERVAN, NEUDEXTA, RADICAVA, RADICAVA ORS, RELYVRIO, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc.)

Recent Developmental Activities in the Amyotrophic Lateral Sclerosis Market
• In May 2022, the company announced that FDA has approved RADICAVA ORS (edaravone), the oral form of edaravone, for the treatment of Amyotrophic Lateral Sclerosis, a neurodegenerative disease that currently has no cure and can progress rapidly. RADICAVA ORS offers the same efficacy as RADICAVA (edaravone), an FDA-approved IV treatment shown in a pivotal trial to help slow the loss of physical function in Amyotrophic Lateral Sclerosis. In March 2022, the company submitted an application to MHLW (Japan) for marketing and manufacturing approval of oral formulation of MT-1186 for treating Amyotrophic Lateral Sclerosis.
• In September 2022, the FDA approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating adults with Amyotrophic Lateral Sclerosis. AMX0035 is an investigational drug not approved for use by EMA; however, MAA was validated for review by EMA'S CHMP in February 2022, and the potential decision is anticipated by 1H 2023.
• In March 2022, the company submitted an application to MHLW (Japan) for marketing and manufacturing approval of oral formulation of MT-1186 for treating Amyotrophic Lateral Sclerosis.
• Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) is the only approved medication that has proven to be effective in lowering down the Pseudobulbar Affect (PBA). Nuedexta acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which Nuedexta exerts therapeutic effects in patients with PBA is unknown. It is approved in the USA and Europe for the treatment of PBA associated with certain neurological conditions such as Amyotrophic Lateral Sclerosis.
• TEGLUTIK was first launched in the European markets after it was approved by US FDA as Tiglutik for the treatment of Amyotrophic Lateral Sclerosis. In 2022, TEGLUTIK (riluzole), the only oral suspension for the treatment of Amyotrophic Lateral Sclerosis, developed and patented by Italfarmaco, has been approved for the Chinese market by the Drug Administration Law of the People's Republic of China.
• Riluzole oral film received the US FDA Orphan Drug designation which is used as adjunctive therapy in the treatment of Amyotrophic Lateral Sclerosis. Aquestive Therapeutics announced the exclusive license to Mitsubishi Tanabe Pharma Holdings America (MTHA) for the commercialization Exservan in the United States and Zambon for the development and commercialization of Exservan in the European Union for the treatment of Amyotrophic Lateral Sclerosis

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis Market Size @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Overview
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a wider group of disorders known as motor neuron diseases caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and muscles throughout the body. Messages from motor neurons in the brain (called upper motor neurons; UMN) are transmitted to motor neurons in the spinal cord and to motor nuclei of the brain (called lower motor neurons; LMN) and from the spinal cord and motor nuclei of the brain to a particular muscle or muscles. ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.

Amyotrophic Lateral Sclerosis Epidemiology Segmentation in the 7MM
• Amyotrophic Lateral Sclerosis Prevalence
• Amyotrophic Lateral Sclerosis Diagnosed Prevalence
• Amyotrophic Lateral Sclerosis Gender-specific Distribution
• Amyotrophic Lateral Sclerosis Mutation-specific Distribution
• Amyotrophic Lateral Sclerosis Type-specific Distribution
• Amyotrophic Lateral Sclerosis Distribution based on Site of onset
• Amyotrophic Lateral Sclerosis Age-specific Distribution

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis Market Outlook @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Marketed Drugs
• Radicava (Mitsubishi Tanabe Pharma Corporation)
• RELYVRIO (AMX0035) Amylyx Pharmaceuticals
• Exservan (Aquestive Therapeutics)
• TIGLUTIK/ TEGLUTIK (ITF Pharma)
• Nuedexta (Avanir Pharmaceuticals)

Amyotrophic Lateral Sclerosis Emerging Drugs
• Tofersen (Biogen/Ionis Pharmaceuticals)
• ION363 (Ionis Pharmaceuticals)
• Masitinib (AB Sciences)
• AIT-101 (LAM-002A) - AI Therapeutics
• Pridopidine (Prilenia Therapeutics)

Amyotrophic Lateral Sclerosis Treatment Market
For the treatment of Amyotrophic Lateral Sclerosis, Riluzole is recommended as first-line therapy in all three regions - Japan, the US, and Europe. Riluzole was first approved in the US by the FDA in 1995, and it was later approved in many other countries in the ensuing decades. It is a medication that appears to prolong the life of some people with Amyotrophic Lateral Sclerosis by at least a few months. Riluzole seems to do two things: block sodium and calcium channels and increase glutamate clearance. Currently, no other drug is globally approved for slowing the progression of Amyotrophic Lateral Sclerosis. RILUTEK, TIGLUTIK, and EXSERVAN are brand names for different formulations of riluzole, a medicine used in the treatment of ALS. RILUTEK is an oral tablet, TIGLUTIK is an oral suspension, and EXSERVAN is an oral film. NEUDEXTA is approved for the treatment of pseudobulbar effects in conditions such as multiple sclerosis and ALS. Recently in June 2022, riluzole oral suspension TIGLUTIK was approved in China. In March 2022, Haisco Pharmaceutical acquired the exclusive rights to develop and commercialize EXSERVAN, for the treatment of Amyotrophic Lateral Sclerosis in China.

Amyotrophic Lateral Sclerosis Market Outlook
Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases mainly involving the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time.

Discover more information of the Amyotrophic Lateral Sclerosis Market Drugs @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Amyotrophic Lateral Sclerosis Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• Amyotrophic Lateral Sclerosis Companies-Helixmith, Sanofi, Denali Therapeutics, Alector,GSK, NeuroSense Therapeutics, Biogen, Ionis,Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and other.
• Amyotrophic Lateral Sclerosis Pipeline Therapies- RILUTEK, TIGLUTIK, EXSERVAN, NEUDEXTA, RADICAVA, RADICAVA ORS, RELYVRIO, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc.)

Table of Content
1. Key Insights
2. Amyotrophic Lateral Sclerosis Market Report Introduction
3. Amyotrophic Lateral Sclerosis Market Overview at a Glance
4. Amyotrophic Lateral Sclerosis Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. SWOT Analysis
8. Disease Background and Overview
9. Amyotrophic Lateral Sclerosis Treatment and Management of ALS
10. European Federation of Neurological Societies (EFNS) guidelines on the Clinical Management of ALS (MALS) (2012)
11. American Association of Neurology (AAN) Guidelines for Care and Management of patients with ALS (2009)
12. Management Algorithm for Respiratory Dysfunction in ALS
13. Management guidelines for ALS in Japan, the United States, and Europe.
14. Epidemiology and Patient Population of the 7MM and China
15. Patient Journey
16. Key Endpoints in Amyotrophic Lateral Sclerosis
17. Amyotrophic Lateral Sclerosis Marketed Drugs
18. Amyotrophic Lateral Sclerosis Emerging Drugs
19. Amyotrophic Lateral Sclerosis: Seven Major Market and China Analysis
20. Unmet Needs
21. Amyotrophic Lateral Sclerosis Market Access and Reimbursement
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

Dive deep into rich insights for new drugs for Amyotrophic Lateral Sclerosis treatment, visit @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.